Neil Kumar - Nov 16, 2024 Form 4 Insider Report for BridgeBio Pharma, Inc. (BBIO)

Role
Chief Executive Officer, Director
Signature
/s/ Brian C. Stephenson, Attorney-in-Fact
Stock symbol
BBIO
Transactions as of
Nov 16, 2024
Transactions value $
-$667,671
Form type
4
Date filed
11/19/2024, 06:15 PM
Previous filing
Aug 20, 2024
Next filing
Nov 20, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BBIO Common Stock Options Exercise +55.5K +1.13% 4.95M Nov 16, 2024 Direct F1
transaction BBIO Common Stock Tax liability -$668K -28.1K -0.57% $23.72 4.92M Nov 16, 2024 Direct F2
holding BBIO Common Stock 1.01M Nov 16, 2024 By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee. F3
holding BBIO Common Stock 996K Nov 16, 2024 By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee. F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BBIO Restricted Stock Units Options Exercise $0 -2.39K -49.99% $0.00 2.4K Nov 16, 2024 Common Stock 2.39K Direct F1, F4
transaction BBIO Restricted Stock Units Options Exercise $0 -33.5K -10% $0.00 302K Nov 16, 2024 Common Stock 33.5K Direct F1, F5
transaction BBIO Restricted Stock Units Options Exercise $0 -19.6K -7.14% $0.00 255K Nov 16, 2024 Common Stock 19.6K Direct F1, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
F2 Represents the number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligation in connection with the vesting of 55,537 shares of Common Stock underlying the Reporting Person's RSUs.
F3 The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose.
F4 The RSUs vested with respect to 1/16th of the underlying shares on May 16, 2021. Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date.
F5 The RSUs vested with respect to 1/16th of the underlying shares on May 16, 2023. Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date.
F6 The RSUs vested with respect to 1/16th of the underlying shares on May 16, 2024. Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date.